Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.

McAdam-Marx C, Nguyen H, Schauerhamer MB, Singhal M, Unni S, Ye X, Cobden D

Clinical therapeutics23 Nov 2016Cited by 20 (Europe PMC)

PMID27889301DOI10.1016/j.clinthera.2016.11.003PepBankPUB-27889301

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, liraglutide and exenatide once weekly gave similar HbA1c reductions at 1 year.
In plain wordsIn adults with type 2 diabetes in routine care, liraglutide lowered HbA1c about as much as exenatide once weekly.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction, liraglutide vs exenatide once weekly
Study
n = 5,141
Comparator
Exenatide once weekly
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adjusted HbA1c change
−0.37%
exenatide QW
Adjusted HbA1c change
−0.37%
liraglutide
Source sentences
Summary
Adjusted mean HbA_1c change at 1 year was -0.37% (95% CI, -0.53% to -0.21%) for exenatide QW and -0.37% (95% CI, -0.55% to -0.18%) for liraglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
Exenatide QW and liraglutide lead to similar HbA_1c and weight reductions at 1 year in the real-world setting.
Summary · context
This retrospective cohort study using national electronic medical record data compared 1-year HbA_1c and weight outcomes in patients with T2D prescribed exenatide QW or liraglutide.
Summary · context
Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date).
Report a problemFND-2788930105
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, liraglutide and exenatide once weekly gave similar weight reductions at 1 year.
In plain wordsIn adults with type 2 diabetes in routine care, liraglutide led to about the same weight loss as exenatide once weekly.
Peptide
Liraglutide
Outcome
No significant changeWeight reduction, liraglutide vs exenatide once weekly
Study
n = 5,141
Comparator
Exenatide once weekly
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adjusted weight change
−2.22 kg
exenatide QW
Adjusted weight change
−2.21 kg
liraglutide
Source sentences
Summary
Mean (adjusted) weight loss was -2.22 kg (95% CI, -3.06 to -1.37 kg) with exenatide QW and -2.21 kg (95% CI, -3.18 to -1.23 kg) with liraglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
Exenatide QW and liraglutide lead to similar HbA_1c and weight reductions at 1 year in the real-world setting.
Summary · context
This retrospective cohort study using national electronic medical record data compared 1-year HbA_1c and weight outcomes in patients with T2D prescribed exenatide QW or liraglutide.
Summary · context
Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date).
Report a problemFND-2788930106
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, HbA1c fell after 1 year of liraglutide.
In plain wordsIn adults with type 2 diabetes in routine care, HbA1c fell after one year of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseAdjusted HbA1c change at 1 year
Study
n = 4,333
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adjusted HbA1c change
−0.37%
liraglutide
Source sentences
Summary
Adjusted mean HbA_1c change at 1 year was -0.37% (95% CI, -0.53% to -0.21%) for exenatide QW and -0.37% (95% CI, -0.55% to -0.18%) for liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study using national electronic medical record data compared 1-year HbA_1c and weight outcomes in patients with T2D prescribed exenatide QW or liraglutide.
Summary · context
Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date).
Report a problemFND-2788930101
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, body weight fell after 1 year of liraglutide.
In plain wordsIn adults with type 2 diabetes in routine care, body weight fell after one year of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseAdjusted weight change at 1 year
Study
n = 4,333
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adjusted weight change
−2.21 kg
liraglutide
Source sentences
Summary
Mean (adjusted) weight loss was -2.22 kg (95% CI, -3.06 to -1.37 kg) with exenatide QW and -2.21 kg (95% CI, -3.18 to -1.23 kg) with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study using national electronic medical record data compared 1-year HbA_1c and weight outcomes in patients with T2D prescribed exenatide QW or liraglutide.
Summary · context
Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date).
Report a problemFND-2788930104
05HumanObservational studyEfficacy outcome
In insulin-naive adults with type 2 diabetes and baseline HbA1c of 7.0% or higher, the adjusted HbA1c reduction was -0.80% with liraglutide and -0.71% with exenatide once weekly (P > 0.05).
In plain wordsIn insulin-naive adults with type 2 diabetes and higher HbA1c, liraglutide and exenatide once weekly lowered HbA1c by a similar amount.
Peptide
Liraglutide
Outcome
DecreaseAdjusted HbA1c change in insulin-naive patients with baseline HbA1c 7.0% or higher
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adjusted HbA1c change
−0.8%
liraglutide
Source sentences
Summary
Adjusted HbA_1c reduction was more pronounced in insulin-naive patients with baseline HbA_1c ≥7.0% (-0.71% and -0.80% for the exenatide QW and liraglutide patients, respectively, P > 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study using national electronic medical record data compared 1-year HbA_1c and weight outcomes in patients with T2D prescribed exenatide QW or liraglutide.
Summary · context
Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date).
Report a problemFND-2788930102
06HumanObservational studyEfficacy outcome
In insulin-naive adults with type 2 diabetes and baseline HbA1c of 9.0% or higher, HbA1c fell strongly with liraglutide, with no significant difference from exenatide once weekly.
In plain wordsIn insulin-naive adults with type 2 diabetes and very high HbA1c, liraglutide lowered HbA1c a lot, similar to exenatide once weekly.
Peptide
Liraglutide
Outcome
DecreaseAdjusted HbA1c change in insulin-naive patients with baseline HbA1c 9.0% or higher
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Adjusted HbA1c change
−1.57%
liraglutide
Source sentences
Summary
Adjusted HbA_1c reduction was more pronounced in insulin-naive patients with baseline HbA_1c ≥7.0% (-0.71% and -0.80% for the exenatide QW and liraglutide patients, respectively, P > 0.05) and ≥9.0% (-1.73% and -1.57% for exenatide QW and liraglutide patients, respectively, P > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study using national electronic medical record data compared 1-year HbA_1c and weight outcomes in patients with T2D prescribed exenatide QW or liraglutide.
Summary · context
Included patients were adults (≥18 years old) with T2D who were GLP-1RA naive when newly prescribed exenatide QW or liraglutide between January 1, 2012, and March 31, 2013 (index date).
Report a problemFND-2788930103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms

Keywords